El Grupo VNET experimentó un aumento del 8.7% gracias al fuerte apoyo institucional y a las condiciones técnicas positivas.

Summary
• VNET Group (VNET) rockets 10.85% intraday to $10.32, defying a -1.18% decline in healthcare tech sector leader McKesson (MCK)
• Apella’s $80M funding round for AI-driven hospital optimization sparks surgical volume growth optimism
• Options chain sees 60,475 shares traded on VNET20260116C10 call, signaling aggressive bullish positioning

VNET Group’s 10.85% intraday surge has ignited a firestorm in healthcare tech circles, driven by Apella’s landmark $80 million Series B funding. With surgical volume gains of 5% already reported by early adopters, the stock’s 9.47–10.395 range reflects a mix of institutional buying and retail frenzy. This move, however, starkly contrasts with the broader sector’s struggles, as McKesson’s -1.18% drag highlights divergent momentum.

Apella’s AI-Driven Surgical Optimization Ignites Institutional Buying
VNET’s 10.85% surge is directly tied to Apella’s $80 million funding announcement, which accelerates deployment of its ambient AI platform across 200+ operating rooms. The round, led by HighlandX and featuring Houston Methodist’s participation, validates Apella’s 5% surgical volume uplift in early adopters. With Horizon’s case duration analytics now enterprise-wide, the platform’s integration into interventional radiology and cardiology workflows has triggered a re-rating of VNET’s 52-week high of $16.13. Institutional buyers are capitalizing on the stock’s 2.397% turnover rate, which remains below its 200-day average of 7.96%.

Healthcare Tech Sector Splits as VNET Defies MCK’s Weakness
While VNET surges, healthcare tech sector leader McKesson (MCK) declines 1.18%, reflecting divergent momentum. VNET’s 10.85% move outpaces peers like Elastic (-1.2%) and GitLab (+0.1%), showcasing its unique positioning in AI-driven hospital optimization. The sector’s 2.47 price/book ratio contrasts with VNET’s 2.47, but its -26.63 P/E ratio highlights speculative positioning. This divergence underscores Apella’s enterprise-scale adoption versus broader sector challenges in monetizing AI applications.

Options Playbook: Capitalizing on VNET’s Volatility with Gamma-Driven Calls
• 200-day average: 7.96 (below current price)
• RSI: 63.59 (neutral)
• MACD: 0.0246 (bullish crossover)
• Bollinger Bands: 8.19–9.57 (current price at 10.32, above upper band)

VNET’s 10.85% surge has created a high-gamma environment, with the VNET20260116C10 and VNET20260116C11 calls offering optimal leverage. The VNET20260116C10 call (strike $10, 65.69 delta) benefits from 0.3435 gamma and 0.0503 theta decay, ideal for a 5% upside scenario (target $10.836). Projected payoff: $836 per contract. The VNET20260116C11 call (strike $11, 0.3049 delta) offers 0.3229 gamma and 0.0348 theta, with a 5% upside payoff of $336. Both contracts see high turnover (60,475 and 17,583 shares) and IV ratios of 65.79% and 66.68%, aligning with sector volatility. Aggressive bulls should target a $10.836 close to trigger 83.6%+ returns on the C10 call.

Backtest VNET Group Stock Performance
The backtest of VNET's performance following an 11% intraday increase from 2022 to the present reveals a strategy that underperformed the benchmark significantly. The strategy's CAGR was only 1.70%, lagging the benchmark by a substantial 39.58%. Although the strategy had a maximum drawdown of 0%, it exhibited high volatility, with a Sharpe ratio of 0.02 and an excess return of -39.58%. This suggests that while the strategy avoided losses during the backtested period, it failed to capitalize on broader market gains, making it less attractive for investors seeking strong overall performance.

VNET’s AI Surge: A Short-Term Gamma Play or Sustainable Breakout?
VNET’s 10.85% move hinges on its ability to maintain surgical volume growth above 5% as Horizon scales. Key levels to watch: 1) $10.395 intraday high (breakout confirmation), 2) 200-day average of $7.96 (support), and 3) MCK’s -1.18% performance as a sector barometer. The VNET20260116C10 call offers a 83.6%+ return if $10.836 is reached by 1/16. Investors should also monitor Apella’s expansion into interventional radiology workflows, which could drive a re-rating above its 52-week high of $16.13. For now, the gamma-driven options play remains valid—target $10.836 by 1/16 or exit at $10.395.